Compare EQBK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | CGEM |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.4M | 904.7M |
| IPO Year | 2015 | 2020 |
| Metric | EQBK | CGEM |
|---|---|---|
| Price | $46.20 | $16.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $51.33 | $30.13 |
| AVG Volume (30 Days) | 58.7K | ★ 956.5K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.58 | N/A |
| Revenue Next Year | $5.11 | $5.20 |
| P/E Ratio | $57.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.04 | $5.68 |
| 52 Week High | $50.07 | $16.74 |
| Indicator | EQBK | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 62.01 |
| Support Level | $44.38 | $11.92 |
| Resistance Level | $46.99 | N/A |
| Average True Range (ATR) | 0.86 | 1.03 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 75.09 | 89.05 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.